Goldman Sachs Group Inc Acer Therapeutics Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	BUY	$0.75 - $1.14 $51 - $78	69 Added 0.08%	88,054 $81,000
Q2 2023 Aug 14, 2023	BUY	$0.75 - $1.14 $51 - $78	69 Added 0.08%	88,054 $81,000
Q1 2023 May 14, 2024	SELL	$0.67 - $3.05 $8 - $39	-13 Reduced 0.01%	87,985 $66,000
Q1 2023 May 11, 2023	SELL	$0.67 - $3.05 $8 - $39	-13 Reduced 0.01%	87,985 $66,000
Q3 2022 May 14, 2024	SELL	$1.28 - $1.6 $6,890 - $8,612	-5,383 Reduced 5.76%	87,998 $122,000
Q3 2022 Nov 10, 2022	SELL	$1.28 - $1.6 $6,890 - $8,612	-5,383 Reduced 5.76%	87,998 $0
Q2 2022 May 14, 2024	BUY	$1.19 - $3.04 $111,123 - $283,878	93,381 New	93,381 $118,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $3.04 $2,203 - $5,630	-1,852 Reduced 1.94%	93,381 $118,000
Q1 2022 May 16, 2022	SELL	$1.98 - $2.98 $217 - $327	-110 Reduced 0.12%	95,233 $276,000
Q4 2021 Feb 14, 2022	BUY	$1.88 - $2.9 $1 - $2	1 Added 0.0%	95,343 $217,000
Q3 2021 Nov 10, 2021	BUY	$2.3 - $2.86 $219,286 - $272,678	95,342 New	95,342 $244,000

365

Ticker ACER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,100,000
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mu...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.